Mary Charles, Faraut Françoise, Lascombe Laurie, Dumon Henri
Laboratoire de Parasitologie, Hopital de la Timone, 13385 Marseille, France.
J Clin Microbiol. 2004 Nov;42(11):5249-55. doi: 10.1128/JCM.42.11.5249-5255.2004.
A real-time PCR was developed to quantify Leishmania infantum kinetoplast DNA and optimized to reach a sensitivity of 0.0125 parasites/ml of blood. In order to analyze the incidence of heterogeneity and number of minicircles, we performed comparative PCR by using the Leishmania DNA polymerase gene as a reporter. Assays performed in both promastigote and amastigote stages showed variations among different L. infantum and Leishmania donovani strains and the stability of the minicircle numbers for a particular strain. Analysis of blood samples from a patient who presented with Mediterranean visceral leishmaniasis confirmed the reliability of such an assay for Leishmania quantification in biological samples and allowed an estimation of positivity thresholds of classical tests used for direct diagnosis of the disease; positivity thresholds were in the range of 18 to 42, 0.7 to 42, and 0.12 to 22.5 parasites/ml for microscopic examination, culture, and conventional PCR, respectively. At the time of diagnosis, parasitemia could vary by a wide range (32 to 188,700 parasites/ml, with a median of 837 parasites/ml), while in bone marrow, parasite load was more than 100 parasites per 10(6) nucleated human cells. After successful therapy, parasitemia levels remain lower than 1 parasite/ml. In the immunocompromised host, relapses correlate with an increase in the level of parasitemia, sometimes scanty, justifying the need for assays with high sensitivity. Such sensitivity allows the detection of Leishmania DNA in the blood of 21% of patients with no history of leishmaniasis living in the Marseilles area, where leishmaniasis is endemic. This technique may be useful for epidemiologic and diagnostic purposes, especially for the quantification of parasitemia at low levels during posttherapy follow-up.
开发了一种实时PCR方法来定量婴儿利什曼原虫动基体DNA,并进行了优化,使其灵敏度达到每毫升血液0.0125个寄生虫。为了分析异质性的发生率和微小环的数量,我们以利什曼原虫DNA聚合酶基因为报告基因进行了比较PCR。在前鞭毛体和无鞭毛体阶段进行的检测显示,不同的婴儿利什曼原虫和杜氏利什曼原虫菌株之间存在差异,且特定菌株的微小环数量具有稳定性。对一名患有地中海内脏利什曼病患者的血液样本进行分析,证实了该检测方法在生物样本中对利什曼原虫定量的可靠性,并估计了用于该疾病直接诊断的经典检测的阳性阈值;显微镜检查、培养和常规PCR的阳性阈值分别为每毫升18至42个、0.7至42个和0.12至22.5个寄生虫。在诊断时,寄生虫血症可能有很大差异(每毫升32至188,700个寄生虫,中位数为每毫升837个寄生虫),而在骨髓中,寄生虫负荷为每10(6)个人类有核细胞超过100个寄生虫。成功治疗后,寄生虫血症水平保持在每毫升低于1个寄生虫。在免疫功能低下的宿主中,复发与寄生虫血症水平的升高相关,有时水平很低,这证明需要高灵敏度的检测方法。这种灵敏度使得能够在马赛地区(利什曼病流行地区)21%无利什曼病病史的患者血液中检测到利什曼原虫DNA。该技术可能对流行病学和诊断目的有用,特别是在治疗后随访期间对低水平寄生虫血症进行定量。